Fludarabine, Cyclophosphamide, and Multiple-Dose Rituximab as Frontline Therapy for Chronic Lymphocytic Leukemia

BACKGROUND: Fludarabine, cyclophosphamide and rituximab (FCR) results in durable responses in patients with previously untreated chronic lymphocytic leukemia (CLL). Previous reports suggest that in patients with relapsed CLL a dose-intensified rituximab regimen increases response rates compared to s...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer
Hlavní autoři: Short, Nicholas J., Keating, Michael J., Wierda, William G., Faderl, Stefan, Ferrajoli, Alessandra, Estrov, Zeev, Smith, Susan C., O'Brien, Susan M.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2015
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4824541/
https://ncbi.nlm.nih.gov/pubmed/26218678
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.29605
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky